Midland Hub for Trials Methodology Research at University of Birmingham
Lead Research Organisation:
University of Birmingham
Department Name: Cancer Sciences
Abstract
Clinical trials test potential treatments in humans to see if they should be approved for wider use in the general population. Any new treatment must be extensively tested to check that it benefits patients, is safe and doesn t have unacceptable side effects. Most often the treatment is a drug, but it could be a medical device, a surgical or physical procedure, a therapy or an intervention such as health promotion. Volunteers are recruited into the clinical trial to undergo the new treatment and usually the trial will include a group who just receive the standard treatment. In this way, the outcome of patients on the new treatment can be compared to the standard to see if it is beneficial. Planning how the trial will be run and making sure it addresses the right questions are important to ensure that the results from the trial will be useful. Interpreting the data that is collected in the trial also needs to guarantee that valid conclusions are reached. The plan for this research is to create a regional facility at the University of Birmingham in which to investigate the best ways to design, conduct and analyse trials, providing advice, support and training to those carrying out trials and to the public. Ultimately this will result in beneficial treatments being delivered to patients more efficiently.
Technical Summary
The aim of the Midland Hub at University of Birmingham is to be a centre of excellence for trials methodology research, providing local and national researchers undertaking trials with innovative methodology for design, conduct and analysis, thereby improving the quality of trials. The Hub will develop existing expertise in trials methodology at Birmingham to deliver a high-quality Research Programme that will be of practical use to the trials community. There is a culture of collaborative working at Birmingham and the Hub will continue to cultivate regional, national and international collaborations to facilitate the successful delivery of research. A comprehensive training programme in trials methodology will train the potential experts of the future and educate trial practitioners in methodology. By providing a mechanism for advice, support and dissemination the Hub will benefit the trials community and ultimately patient care.
Our proposed research programme centres around the current specialist methodological areas but the wealth of expertise will enable us to develop new research themes identified as important by the clinical trials community. There are seven key research themes at Birmingham: (1) Quality of life evaluation for clinical and health economic assessment; (2) Discovery and evaluation of diagnostic, prognostic and predictive biomarkers; (3) Methods to obtain reliable conclusions and involve users; (4) Bayesian methods in design and analysis of trials; (5) E-trials; (6) Systematic review for clinical and health economic assessment; (7) Education in trial methodology. Methodological expertise within the Research Programme feeds into all major areas within the trial process i.e. pre-trial development, trial design and set-up, trial conduct, trial analysis and evidence synthesis.
In summary, Birmingham is at the heart of the trials community, providing academic expertise based on real-life trial experience, ready access to a wealth of datasets that can be used for methodology research, real situations in which to implement new methodology and direct support to many members of the clinical trial community. As one of the leading centres in the UK for clinical trials, the University of Birmingham is the ideal location for the Midland Hub for Trials Methodology Research.
Our proposed research programme centres around the current specialist methodological areas but the wealth of expertise will enable us to develop new research themes identified as important by the clinical trials community. There are seven key research themes at Birmingham: (1) Quality of life evaluation for clinical and health economic assessment; (2) Discovery and evaluation of diagnostic, prognostic and predictive biomarkers; (3) Methods to obtain reliable conclusions and involve users; (4) Bayesian methods in design and analysis of trials; (5) E-trials; (6) Systematic review for clinical and health economic assessment; (7) Education in trial methodology. Methodological expertise within the Research Programme feeds into all major areas within the trial process i.e. pre-trial development, trial design and set-up, trial conduct, trial analysis and evidence synthesis.
In summary, Birmingham is at the heart of the trials community, providing academic expertise based on real-life trial experience, ready access to a wealth of datasets that can be used for methodology research, real situations in which to implement new methodology and direct support to many members of the clinical trial community. As one of the leading centres in the UK for clinical trials, the University of Birmingham is the ideal location for the Midland Hub for Trials Methodology Research.
Publications

Hemming K
(2011)
Fetal growth and birthweight standards as screening tools: methods for evaluating performance Assessing the efficacy of birthweight standards
in BJOG: An International Journal of Obstetrics & Gynaecology

Zeegers MP
(2010)
The West Midlands Bladder Cancer Prognosis Programme: rationale and design.
in BJU international



Calvert M
(2012)
Population health status of South Asian and African-Caribbean communities in the United Kingdom.
in BMC health services research

Lilford RJ
(2014)
Protocol for evaluation of the cost-effectiveness of ePrescribing systems and candidate prototype for other related health information technologies.
in BMC health services research

Kirkby HM
(2011)
Using e-mail recruitment and an online questionnaire to establish effect size: A worked example.
in BMC medical research methodology

Crowther MJ
(2012)
Individual patient data meta-analysis of survival data using Poisson regression models.
in BMC medical research methodology

Ferrante Di Ruffano L
(2017)
Test-treatment RCTs are susceptible to bias: a review of the methodological quality of randomized trials that evaluate diagnostic tests.
in BMC medical research methodology

Ferrante Di Ruffano L
(2017)
Research waste in diagnostic trials: a methods review evaluating the reporting of test-treatment interventions.
in BMC medical research methodology
Description | Department of Health Research Support Facility funded PhD studentship |
Amount | £61,556 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 05/2010 |
End | 06/2013 |
Description | European Commission Seventh Framework Programme (FP7) |
Amount | £250,000 (GBP) |
Organisation | European Commission |
Department | Seventh Framework Programme (FP7) |
Sector | Public |
Country | European Union (EU) |
Start | 12/2011 |
End | 12/2016 |
Description | European Commission Seventh Framework Programme (FP7) |
Amount | £300,000 (GBP) |
Organisation | European Commission |
Department | Seventh Framework Programme (FP7) |
Sector | Public |
Country | European Union (EU) |
Start | 01/2011 |
End | 01/2015 |
Description | HTA |
Amount | £742,492 (GBP) |
Organisation | National Institute for Health Research |
Department | Health Technology Assessment Programme (HTA) |
Sector | Public |
Country | United Kingdom |
Start | 08/2011 |
End | 03/2014 |
Description | HTA 09/22/117 |
Amount | £1,621,734 (GBP) |
Funding ID | 09/22/117 |
Organisation | National Institute for Health Research |
Department | Health Technology Assessment Programme (HTA) |
Sector | Public |
Country | United Kingdom |
Start | 03/2011 |
End | 10/2015 |
Description | HTA 10/36/02 |
Amount | £200,529 (GBP) |
Funding ID | HTA/10/36/02 |
Organisation | National Institute for Health Research |
Department | Health Technology Assessment Programme (HTA) |
Sector | Public |
Country | United Kingdom |
Start | 12/2011 |
End | 05/2013 |
Description | HTA 10/44/01 |
Amount | £241,472 (GBP) |
Funding ID | HTA/10/44/01 |
Organisation | National Institute for Health Research |
Department | Health Technology Assessment Programme (HTA) |
Sector | Public |
Country | United Kingdom |
Start | 01/2012 |
End | 06/2014 |
Description | MRC |
Amount | £49,540 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2011 |
End | 02/2012 |
Description | MRC Hub Network funding |
Amount | £10,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2011 |
End | 01/2012 |
Description | MRC Partnership Grant for (PROGRESS) |
Amount | £980,410 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2012 |
End | 03/2015 |
Description | NIHR Doctoral Fellowship |
Amount | £300,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 01/2012 |
End | 12/2015 |
Description | NIHR National School Primary Care Research |
Amount | £85,260 (GBP) |
Organisation | National Institute for Health Research |
Department | School for Primary Care Research |
Sector | Academic/University |
Country | United Kingdom |
Start | 05/2011 |
End | 06/2014 |
Description | NIHR Postdoctoral Research Fellowship |
Amount | £300,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 09/2009 |
End | 10/2012 |
Description | NIHR Programme Grant |
Amount | £1,987,326 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 01/2011 |
End | 01/2016 |
Description | NIHR RfPB |
Amount | £250,000 (GBP) |
Organisation | National Institute for Health Research |
Department | Research for Patient Benefit |
Sector | Public |
Country | United Kingdom |
Start | 01/2011 |
End | 01/2013 |
Description | Nova Scotia Health Research Foundation Establishment Grant Competition |
Amount | £96,780 (GBP) |
Organisation | Nova Scotia Health Research Foundation |
Sector | Charity/Non Profit |
Country | Canada |
Start | 08/2011 |
End | 08/2013 |
Description | Post Graduate overseas work experience placement scholarship College of Medicine and Denistry, University of Birmingham |
Amount | £3,100 (GBP) |
Organisation | University of Birmingham |
Department | College of Medical and Dental Sciences |
Sector | Academic/University |
Country | United Kingdom |
Start | 02/2012 |
End | 03/2012 |
Description | Queen Elizabeth hospital Birmingham Charity |
Amount | £69,432 (GBP) |
Organisation | Queen Elizabeth Hospital Birmingham Charity (QEHB) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2011 |
End | 09/2012 |
Title | Developed numerous techniques for performing and estimating multivariate (random effects) meta-analysis models |
Description | Developed numerous techniques for performing and estimating multivariate (random effects) meta-analysis models which synthesis multiple correlated outcomes. See associated published papers |
Type Of Material | Data analysis technique |
Year Produced | 2009 |
Provided To Others? | Yes |
Impact | See associated published papers. Also, a workshop about how to perform multivariate meta-analysis at the RSS, and the methods have been implemented within the STATA module 'mvmeta' |
Title | a database of all IPD meta-analysis articles published up to March 2009 |
Description | Developed (with Hub member Ghada Abo-Zaid) a database of all IPD meta-analysis articles published up to March 2009 |
Type Of Material | Database/Collection of Data/Biological Samples |
Year Produced | 2010 |
Provided To Others? | Yes |
Impact | Empirical research regarding how IPD meta-analyses are undertaken, how IPD is collected, the biases involved, and the necessary reporting standards and guidelines for improvement |
Description | Biologic therapies for rheumatoid and psoriatic arthritis: Consensus models for decision-making |
Organisation | Medical Research Council (MRC) |
Department | MRC ConDuCT Trials Methodology Hub |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | extensive expertise in HTA modelling, and developed the Birmingham Rheumatoid Arthritis Model, which has been used to inform a number of NICE technological appraisals |
Impact | The immediate output will be the consensus statement which will set out the preferred model for decision-making in biologic therapies, as proposed by our independent group of clinicians, modelling experts, and regulators. We will also establish a collaborative modelling group through this process, and put together a grant application as described above. Finally, we will document the process through which consensus was achieved, along with insights for the successful development of preferred decision models in other disease areas |
Start Year | 2011 |
Description | CTRad: Clinical Trials in Radiotherapy |
Organisation | National Cancer Research Institute (NCRI) |
Department | NCRI Clinical and Translational Radiotherapy Research Working Group |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Chair of Phase III Workstream |
Collaborator Contribution | Methodology Workshop and papers in preparation |
Impact | Methodology Workshop and papers in preparation |
Start Year | 2009 |
Description | Cochrane Prognosis Methods Group |
Organisation | University of Oxford |
Department | Department of Statistics |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Richard Riley is co-convenor of the International Cochrane Prognosis Methods Group (initiated in 2006) alongside Jill Hayden (Canada), Doug Altman (UK), Karel Moons (The Netherlands), and Katrina Williams (Australia). |
Collaborator Contribution | I am a co-convenor of the International Cochrane Prognosis Methods Group (initiated in 2006) alongside Jill Hayden (Canada), Doug Altman (UK), Karel Moons (The Netherlands), and Katrina Williams (Australia). We continually provide advice to national and international researchers conducting systematic reviews of prognosis studies. The convenors also provide recommendations for how prognosis information should be included in Cochrane Reviews of interventions, and if and when the Collaboration should formally introduce reviews of prognosis studies |
Impact | We continually provide advice to national and international researchers conducting systematic reviews of prognosis studies. The convenors also provide recommendations for how prognosis information should be included in Cochrane Reviews of interventions, and if and when the Collaboration should formally introduce reviews of prognosis studies |
Start Year | 2006 |
Description | Reporting guidelines for Risk Prediction Models |
Organisation | University of Oxford |
Department | Department of Statistics |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Richard Riley is part of a collaboration (led by Gary Collins and Doug Altman, Oxford, and Karel Moons, Utrecht) developing reporting guidelines for prediction models. The group has produced an initial set of guidelines, that are currently being refined. |
Collaborator Contribution | I am part of a collaboration (led by Gary Collins and Doug Altman, Oxford, and Karel Moons, Utrecht) developing reporting guidelines for prediction models. The group has produced an initial set of guidelines, that are currently being refined. |
Impact | The group has produced an initial set of guidelines, that are currently being refined. |
Start Year | 2011 |
Description | The PROGRESS initiative |
Organisation | University College London |
Department | Institute of Epidemiology and Health Care |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Richard Riley co-lead of the PROGRESS initiative (PROGnosis RESearch Strategy) alongside Harry Hemmingway, UCL, and Doug Altman, Oxford. Since 2009 we have organised 3 workshops that brought together 25 national and international experts (including journal editors, clinicians, statisticians, epidemiologists, and economists) across multiple disease fields to develop a framework for improving prognosis research. These workshops have led to a series of 4 articles that are being revised for the BMJ/PLoS Med, describing the four key aspects of prognosis research: overall prognosis, prognostic factors, prognostic models and predictive factors for stratified medicine. These articles serve as an introduction to the field of prognosis, and why it is important and the necessary steps toward improvement. |
Collaborator Contribution | I am a co-lead of the PROGRESS initiative (PROGnosis RESearch Strategy) alongside Harry Hemmingway, UCL, and Doug Altman, Oxford. Since 2009 we have organised 3 workshops that brought together 25 national and international experts (including journal editors, clinicians, statisticians, epidemiologists, and economists) across multiple disease fields to develop a framework for improving prognosis research. These workshops have led to a series of 4 articles that are being revised for the BMJ/PLoS Med, describing the four key aspects of prognosis research: overall prognosis, prognostic factors, prognostic models and predictive factors for stratified medicine. These articles serve as an introduction to the field of prognosis, and why it is important and the necessary steps toward improvement. |
Impact | 3 workshops that brought together 25 national and international experts (including journal editors, clinicians, statisticians, epidemiologists, and economists) across multiple disease fields to develop a framework for improving prognosis research. These workshops have led to a series of 4 articles that are being revised for the BMJ/PLoS Med, describing the four key aspects of prognosis research: overall prognosis, prognostic factors, prognostic models and predictive factors for stratified medicine. These articles serve as an introduction to the field of prognosis, and why it is important and the necessary steps toward improvement |
Start Year | 2009 |
Description | 'Quality of Life Assessment in Cancer Research' workshop-Medical School, University of Birmingham 17.02.2011 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Participants (approx 80) attended a workshop of presentations which evoked questions, debates and discussions request for further sessions |
Year(s) Of Engagement Activity | 2011 |
Description | 'Quality of Life Assessment in Cancer Research' workshop-Medical School, University of Birmingham-17.11.2011 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Participants (approx 80) attended a workshop of presentations which evoked questions, debates and discussions Request for further sessions |
Year(s) Of Engagement Activity | 2011 |
Description | 2nd Clinical Trial Methodology Conference, Edinburgh |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Type Of Presentation | Poster Presentation |
Geographic Reach | National |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Using systematic reviews to identify research gaps - a case study 131I-mIBG for the treatment of neuroblastoma in children Wilson, J et al represented Midland hub for trials methodology research |
Year(s) Of Engagement Activity | 2013 |
URL | http://www.methodologyconference2013.org.uk/ |
Description | 2nd Clinical Trials Methodology Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Type Of Presentation | Poster Presentation |
Geographic Reach | National |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design Josephine N Khan1*, Christina Yap2, Richard Clark3, Nicola Fenwick1, David Marin4 1 Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK 2 MRC Midland Hub for Trials Methodology Research, University of Birmingham, Birmingham, UK 3 Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK 4 Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK Represented Midland Hub for Trials Methodology Research |
Year(s) Of Engagement Activity | 2013 |
URL | http://www.methodologyconference2013.org.uk/ |
Description | 2nd Clinical Trials Methodology Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Type Of Presentation | Poster Presentation |
Geographic Reach | National |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Challenges in the development of prognostic models utilising clinical trials data Kym IE Snell1, Lucinda J Billingham1,2, Deborah D Stocken3, Richard D Riley1 MRC Midland Hub for Trials Methodology Research, University of Birmingham, UK 2 Cancer Research UK Clinical Trials Unit, University of Birmingham, UK 3 Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK Email: kxs105@bham.ac.uk Represented Midland Hub for Trials Methodology Research |
Year(s) Of Engagement Activity | 2013 |
URL | http://www.methodologyconference2013.org.uk/ |
Description | 2nd Clinical Trials Methodology Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Type Of Presentation | Poster Presentation |
Geographic Reach | National |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | FLEXIBLE TRIAL DESIGN IN A RARE CONDITION Veronica Moroz1, Keith Wheatley1, 2, Martin McCabe3 1 Cancer Research UK Clinical Trials Unit, University of Birmingham; 2 MRC Midland Hub for Trials Methodology Research, University of Birmingham; 3 Institute of Cancer Sciences , Manchester Academic Health Science Centre , University of Manchester. Represented Midland Hub for Trials Methodology Research |
Year(s) Of Engagement Activity | 2013 |
URL | http://www.methodologyconference2013.org.uk/ |
Description | Meeting on Stratified Medicine |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Workshop on stratified medicine dissemination of knowledge on stratified medicine |
Year(s) Of Engagement Activity | 2010 |
Description | Oral Presentation at NCRI Cancer Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Speaker on 'Adaptive Trial Designs that Incorporate Biomarkers' Provided knowledge for clinicians |
Year(s) Of Engagement Activity | 2011 |
Description | Oral Presentation at World Conference on Lung Cancer |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Speaker to an international audience of lung cancer clinicians on 'How to design a meta-analysis in biomarkers' Provided knowledge for clinicians |
Year(s) Of Engagement Activity | 2009 |
Description | Oral Presentation at World Conference on Lung Cancer Young Investigators Day |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Speaker to international audience of young lung cancer clinicians on 'Trial Designs for Biomarker assessment' Provided knowledge for clinicians |
Year(s) Of Engagement Activity | 2011 |
Description | Poster presentation at NCRI Cancer Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Poster presentation at NCRI Cancer Conference 'Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency Indications' Knowledge for clinicians |
Year(s) Of Engagement Activity | 2011 |
Description | Poster presentation at NCRI Cancer Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Poster Presentation at NCRI Cancer Conference 'Quality-adjusted survival analysis using the integrated quality survival product: comparison of utilities and profile measures using a large phase III randomised clinical trial in lung cancer' knowledge for clinicians |
Year(s) Of Engagement Activity | 2011 |
Description | Seminar at Keele Clinical Trials Unit |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Dissemination about Trials Methodology and Hubs Potential collaboration on future trial designs |
Year(s) Of Engagement Activity | 2010 |
Description | Seminar at Nottingham Clinical Trials Unit |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | Dissemination about trials methodology and Hub Potential collaboration on future trial designs |
Year(s) Of Engagement Activity | 2011 |
Description | Seminar at Taunton Hospital |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | 20 clinicians attended and learnt about interpreting results from lung cancer trials Improved knowledge of clinical community |
Year(s) Of Engagement Activity | 2009 |
Description | Swedish Lung Cancer Meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Primary Audience | Health professionals |
Results and Impact | National meeting of Swedish thoracic Oncologists influence decisions regarding strategy for biomarker trials in lung cancer |
Year(s) Of Engagement Activity | 2010 |